Categories Health Care, IPO

IPO news: Cingulate is making its market debut this week, here’s what to know

The company will offer 4.6 million shares at a price range of $10 to $12 to raise $50.1 million

The biopharmaceuticals market was valued at approx. $325.17 billion in 2020 and it is expected to grow at a CAGR of 7.3% over the next five years, based on data from Mordor Intelligence. There is always a huge demand for medicines that are easier to administer and that are less expensive. One such company that is working on addressing these issues is Cingulate Inc. and this biopharma company is set to make its market debut this week.

IPO details

Cingulate Inc. is slated to go public on Thursday, October 7. The company will begin trading on NASDAQ under the ticker symbol CING. It will offer 4.6 million shares at a price range of $10 to $12 to raise $50.1 million. The IPO will be managed by a group of underwriters led by Oppenheimer & Co.

Company intro

Cingulate is a clinical stage biopharmaceutical company focused on developing medicines that can help patients suffering from medical conditions with burdensome daily dosing regimens. The company’s initial efforts are focused on the treatment of Attention Deficit/Hyperactivity Disorder or ADHD.

Stimulants are the most commonly prescribed class of medications for ADHD, comprising 90% of all medication prescriptions for this condition in the US. Cingulate’s two proprietary first-line stimulant medications, CTx-1301 and CTx-1302, are being developed for the treatment of ADHD in children, adolescents and adults.

The company’s products are designed to take effect immediately, last for an entire day, eliminate the need for a booster dose, and reduce or eliminate rebound/crash symptoms. Cingulate plans to start Phase 3 trials for CTx-1301 in the fourth quarter of 2021 with results expected in late 2022, and a Phase 1/2 bioavailability study for CTx-1302 in early 2022.


Cingulate has not begun generating revenue from its products. In 2020, the company incurred a net loss of $7.1 million compared to a loss of $11.5 million in 2019. For the first six months of 2021, Cingulate posted a net loss of $2.7 million versus a loss of $4.8 million in the same period a year ago.

Market opportunity

In the US, approx. 6.4 million, or 11% of children and adolescents aged 4-17 have been diagnosed with ADHD. Of this, 80% receive treatment and 65% show clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence in the US is estimated at approx. 4.4% of the population.

The adult ADHD market is growing approx. 10% year-over-year. Total ADHD medication sales in the US have grown approx. 8% each year since 2010 with sales of all ADHD medications reaching around $18.3 billion in 2020.

Click here to read more IPO-related stories

Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!

Most Popular

Disney (DIS): A look at the major winning points for its streaming business

Shares of the Walt Disney Company (NYSE: DIS) have been rallying since the entertainment leader delivered strong results for its third quarter of 2022 a day ago. The stock was

KSS Stock: After terminating sale talks, what awaits Kohl’s this year

Kohl’s Corporation (NYSE: KSS) has been on investors' radar ever since the retailer put itself up for sale earlier this year, after coming under pressure from activist investors. Putting an

Walt Disney Company (DIS) Q3 revenues, earnings beat Street view

Entertainment behemoth The Walt Disney Company (NYSE: DIS) on Wednesday reported higher revenues and earnings for the third quarter of 2022. The results also topped expectations. Third-quarter revenues of the Los

Add Comment
Viewing Highlight